Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
REHOVOT, Israel and NEW YORK, March 07, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference, and the 28th Annual Oppenheimer Healthcare Conference.
| 30th Annual ROTH Conference | ||
| Date: | Monday, March 12 | |
| Time: | 8:30am Pacific Time/11:30am Eastern Time | |
| Location: | Ritz Carlton, Laguna Niguel, California - BLUE Track - Salon 2 | |
| Webcast: | http://wsw.com/webcast/roth32/aitb/ | |
| Oppenheimer 28th Annual Healthcare Conference | ||
| Date: | Tuesday, March 20 | |
| Time: | 4:30pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
